Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide plus apatinib for recurrent/metastatic small cell lung cancer
ChiCTR-OIC-17011013Phase 2Not yet recruiting
- Sponsor
- Affiliated Tumor Hospital of General Hospital of Ningxia Medical University
- Start
- Apr 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide and Rivoceranib in small cell lung cancer (SCLC), sponsored by Affiliated Tumor Hospital of General Hospital of Ningxia Medical University. Primary endpoint: Progression-free survival (PFS). Planned start Apr 2017; status: not yet recruiting.
02
Drugs
etoposideRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-OIC-17011013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011013.